Showing results (121-130 of 165) with videos related to

Sort By:
Pageof 17
Blood|April 18, 2013
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus projectGiovanni Barosi, Ruben Mesa, Guido Finazzi, et al.
British Journal of Clinical Pharmacology|June 5, 2023
Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New ZealandPaul K L Chin, Kellie Charles, Bridin Murnion, et al.
Leukemia|July 22, 2022
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben Mesa, Claire Harrison, Stephen T Oh, et al.
Blood Advances|April 12, 2023
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trialsSrdan Verstovsek, Ruben Mesa, Vikas Gupta, et al.
JAMA Oncology|July 17, 2015
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical TrialAnimesh Pardanani, Claire Harrison, Jorge E Cortes, et al.
Elife|April 30, 2021
ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry dataJames W Opzoomer, Jessica A Timms, Kevin Blighe, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Therapeutic Advances in Hematology|April 4, 2022
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK studyAdam J Mead, Nauman M Butt, Waseem Nagi, et al.
Blood Advances|May 31, 2024
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosisAaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, et al.
British Journal of Haematology|June 1, 2021
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutationsNicole Naumann, Johannes Lübke, William Shomali, et al.
Pageof 17